In order to evaluate the progression of renal disease, Munich-Wistar rats were submitted to 5/6 nephrectomy and given whole-body x- or γ-irradiation with or without remnant kidney protection or were submitted only to remnant kidney irradiation. All groups received a single 6-Gy dose immediately after surgery. Whole-kidney function, glomerular hemodynamics, 24-hour proteinuria and histopathology were assessed 60 days after surgery and irradiation. The irradiated nephrectomized animals presented whole-kidney function parameters comparable to those of normal rats. In addition, they were less hypertensive and had higher hematocrit. They showed glomerular hyperfiltration and hypertension even greater than their respective nephrectomized controls. However, the interrelations among the glomerular filtration determinants were somewhat different in irradiated animals. Their 24-hour proteinuria was significantly lower and the sclerosis index and tubulointerstitial injury score were markedly smaller. Among irradiated animals, the worst sclerosis index was observed in those with a shielded remnant kidney and the best in those without protection of the remnant kidney. This led us to speculate about a possible influence of resident mesangial cells on the early events following renal mass ablation and on the maintenance of subsequent physiopathologic changes. Therefore, radiation undoubtedly provoked a beneficial change in the course of renal disease when the renal mass ablation model was employed. Many factors could have contributed to this favorable feature including lower levels of systemic arterial pressure, less increment in ΔP, diminished proteinuria, and maintenance of tubulointerstitial space integrity. Our data also suggest that development of glomerulosclerosis seems to be determined by events occurring immediately after injury.

Keywords:
X-ray irradiation, Chronic renal failure, Glomerular hemodynamics
1.
Klahr S, Schreiner G, Ichikawa I: The progression of renal disease. N Engl J Med 1988; 318:1657–1666.
2.
Hebert LA, Bay WH: On the natural tendency to progressive loss of remaining kidney function in patients with impaired renal function. Med Clin North Am 1990;74:1011–1024.
3.
Hostetter TH, Olson JL, Rennke HG, Venkatachalam MA, Brenner BM: Hyperfiltration in remnant nephrons: A potentially adverse response to renal ablation. Am J Physiol 1981;241:F85–F93.
4.
Yoshida Y, Fogo A, Ichikawa I: Glomerular hemodynamics changes vs. hypertrophy in experimental glomerular sclerosis. Kidney Int 1989;35:654–660.
5.
Cortes P, Riser BL, Zhao X, Narins RG: Glomerular volume expansion and mesangial cell mechanical strain: Mediators of glomerular pressure injury. Kidney Int 1994;45(suppl 45):11–16.
6.
Herrera-Acosta J: The role of systemic and glomerular hypertension in progressive glomerular injury. Kidney Int 1994;45(suppl 45):6–10.
7.
Okada H, Strutz F, Danoff TM, Neilson EG: Possible pathogenesis of renal fibrosis. Kidney Int 1996;49(suppl 54):37–38.
8.
Purkerson ML, Tollefsen DM, Klahr S: N-desulfated/acetylated heparin ameliorates the progression of renal disease in rats with subtotal renal ablation. J Clin Invest 1988;81:69–74.
9.
Tapp DC, Wortham WG, Addison JF, Hammonds DN, Barnes JL, Venkatachalam MA: Food restriction retards body growth and prevents end-stage renal pathology in remnant kidneys of rats regardless of protein intake. Lab Invest 1989;60:184–195.
10.
Cameron JS: Proteinuria and progression in human glomerular diseases. Am J Nephrol 1990;10(suppl 1):81–87.
11.
Guijarro C, Kasiske BL, Kim Y, O’Donnell MP, Lee HS, Keane WF: Early glomerular changes in rats with dietary-induced hypercholesterolemia. Am J Kidney Dis 1995;26:152–161.
12.
Floege J, Burns MW, Alpers CE, Yoshimura A, Pritzl P, Gordon K, Seifert RA, Bowen-Pope DF, Couser WG, Johnson RJ: Glomerular cell proliferation and PDGF expression precede glomerulosclerosis in the remnant kidney model. Kidney Int 1992;41:297–309.
13.
Van Goor H, Ding G, Kees-Folts D, Grond J, Schreiner GF, Diamond JR: Biology of disease. Macrophages and renal disease. Lab Invest 1994;71:456–464.
14.
Diamond JR: Macrophages and progressive renal disease in experimental hydronephrosis. Am J Kidney Dis 1995;26:133–140.
15.
Nath KA: Tubulointerstitial changes as a major determinant in the progression of renal damage. Am J Kidney Dis 1992;20:1–17.
16.
Strutz F, Müller GA: On the progression of chronic renal disease. Nephron 1995;69:371–379.
17.
Diamond JR, Pesek-Diamond I: Sublethal X-irradiation during acute puromycin nephrosis prevents late renal injury: Role of macrophages. Am J Physiol 1991;260:F779–F786.
18.
Diamond JR, Van Goor H, Ding G, Engelmyer E: Myofibroblasts in experimental hydronephrosis. Am J Pathol 1995;146:121–129.
19.
Harris KPG, Schreiner GF, Klahr S: Effect of leukocyte depletion on the function of the postobstructed kidney in the rat. Kidney Int 1989;36:210–215.
20.
Mattana J, Singhal PC: Macrophage Fc receptor activity modulates mesangial cell proliferation and matrix synthesis. Am J Physiol 1994;266:F568–F575.
21.
Henry RJ, Cannan DC, Winkelmann JW: Clinical Chemistry: Principles and Techniques. New York, Harper & Row, 1974, pp 423–435.
22.
Teixeira VPC, Boim MA, Segreto HRC, Schor N: Acute, subacute, and chronic x-ray effects on glomerular hemodynamics in rats. Ren Fail 1994;16:457–470.
23.
Deen WM, Robertson CR, Brenner BM: A model of glomerular ultrafiltration in the rat. Am J Physiol 1972;223:1178–1183.
24.
Deen WM, Troy JL, Robertson CL, Brenner BM: Dynamics of glomerular ultrafiltration in the rat. IV. Determination of the ultrafiltration coefficient. J Clin Invest 1973;52:1500–1508.
25.
Vürek GG, Pegram SE: Fluorimetric method for the determination of nanogram quantities of inulin. Anal Biochem 1966;16:409–419.
26.
Führ J, Kaczmarczyk J, Kruttgen CD: Eine einfache colorimetrische Methode zur Inulinbestimmung für Nierenclearance-Untersuchungen bei Stoffwechselgesunden und Diabetikern. Klin Wochenschr 1955;33:729–730.
27.
Viets JW, Deen HM, Troy JL, Brenner BM: Determination of serum protein concentration in nanoliter blood samples using fluorescamine or O-phthalaldeyde. Anal Biochem 1978;88:513–521.
28.
Smith HW, Finkelstein N, Aliminosa L, Crawford B, Graber M: The renal clearances of substituted hippuric acid derivatives and other aromatic acids in dog and man. J Clin Invest 1945;24:388–404.
29.
Raij L, Azar S, Keane W: Mesangial immune injury, hypertension, and progressive glomerular damage in Dahl rats. Kidney Int 1984;26:137–143.
30.
Reyes AA, Karl IE, Yates J, Klahr S: Low plasma and renal tissue levels of L-arginine in rats with obstructive nephropathy. Kidney Int 1994;45:782–787.
31.
Reyes AA, Porras BH, Chasalow FI, Klahr S: L-Arginine decreases the infiltration of the kidney by macrophages in obstructive nephropathy and puromycin-induced nephrosis. Kidney Int 1994;45:1346–1354.
32.
Van Goor H, Van der Horst MLC, Fidler V, Grond J: Glomerular macrophage modulation affects mesangial expansion in the rat after renal ablation. Lab Invest 1992;66:564–571.
33.
Travis EL: Cellular response to radiation; in Primer of Medical Radiobiology. Chicago, Year Book Medical, 1975, pp 59–81.
34.
Lichter AS, Lawrence TS: Recent advances in radiation oncology. N Engl J Med 1995;332:371–379.
35.
Johnson RJ: The glomerular response to injury: Progression or resolution? Kidney Int 1994;45:1769–1782.
36.
Schrijver G, Bogman JJT, Assman KJM, De Waal RMW, Robben HCM, Van Gasteren H, Koene AP: Anti-GBM nephritis in the mouse: Role of granulocytes in the heterologous phase. Kidney Int 1990;38:86–95.
37.
Bogman MJJT, Cornelissen IMHA, Berden JHM, De Jong J, Koene RAP: A comparative study of total body irradiation as a method of inducing granulocyte depletion in mice. J Immunol Methods 1984;70:31–38.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.